Status:

COMPLETED

An Open, Randomized Pilot Study to Evaluate the Use of Basiliximab With an Optimized Cyclosporine Dosing on Renal Function in "de Novo" Liver Transplantation.

Lead Sponsor:

Novartis

Conditions:

Liver Transplantation

Eligibility:

All Genders

18-75 years

Phase:

PHASE4

Brief Summary

The objectives of the study are:To compare the renal function of a quadruple immunosuppressive regimen (including basiliximab in combination with an optimized cyclosporine dose during the first weeks ...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • First cadaveric liver transplant
  • ABO identical or compatible graft
  • Exclusion Criteria
  • Multiple organ transplant
  • renal impairment defined as glomerular filtration rate (GFR) \< 30 ml/min
  • Fulminant liver failure
  • Other protocol-defined exclusion criteria may apply.

Exclusion

    Key Trial Info

    Start Date :

    May 1 2002

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    Estimated Enrollment :

    48 Patients enrolled

    Trial Details

    Trial ID

    NCT00343226

    Start Date

    May 1 2002

    Last Update

    August 25 2010

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

    An Open, Randomized Pilot Study to Evaluate the Use of Basiliximab With an Optimized Cyclosporine Dosing on Renal Function in "de Novo" Liver Transplantation. | DecenTrialz